{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:40:45Z","timestamp":1784000445603,"version":"3.55.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has been transformative for the treatment of B-cell malignancies, with CD19- and CD22-directed CARs being prime examples. However, immunoediting and ensuing antigen loss remain the major obstacles to curative therapy in up to 25% of patients. For example, to achieve the CD19-negative phenotype, malignant cells can pick from a broad array of mechanisms, including focal loss-of-function mutations, dysregulated trafficking to the cell surface, alternative splicing, and lineage switching. In other cases, where resistance is mediated by insufficient antigen density, trogocytosis has been proposed as a possible underlying mechanism. To overcome these barriers, compensatory strategies will be needed, which could include using combinatorial CARs, harnessing epitope spreading, and targeting tumor neoantigens.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000381","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:13:32Z","timestamp":1558754012000},"page":"217-222","source":"Crossref","is-referenced-by-count":25,"title":["Escape From ALL-CARTaz"],"prefix":"10.1097","volume":"25","author":[{"given":"Sisi","family":"Zheng","sequence":"first","affiliation":[{"name":"Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Asnani","sequence":"additional","affiliation":[{"name":"Cancer Pathobiology, Children's Hospital of Philadelphia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Thomas-Tikhonenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib10-20230924","first-page":"224ra25","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/imt.15.6","article-title":"CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?","volume":"7","year":"2015","journal-title":"Immunotherapy"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MOH.0000000000000190","article-title":"T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia","volume":"22","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/2040620718774268","article-title":"Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?","volume":"9","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","year":"2018","journal-title":"Cell"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","year":"2002","journal-title":"Nat Immunol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell\u2013based immunotherapy","volume":"16","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","year":"2018","journal-title":"Nature"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","volume":"171","year":"2015","journal-title":"Br J Haematol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","year":"2015","journal-title":"Cancer Discov"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","year":"1997","journal-title":"Mol Immunol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib30-20230924","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","year":"2018","journal-title":"Mol Cell Biol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.4049\/jimmunol.171.8.4062","article-title":"The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment","volume":"171","year":"2003","journal-title":"J Immunol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.3324\/haematol.2018.203521","article-title":"Molecular analysis of a CD19-negative diffuse large B-cell lymphoma","volume":"104","year":"2019","journal-title":"Haematologica"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"e11752","DOI":"10.7554\/eLife.11752","article-title":"A new view of transcriptome complexity and regulation through the lens of local splicing variations","volume":"5","year":"2016","journal-title":"Elife"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","year":"2017","journal-title":"J Immunother"},{"key":"bib35-20230924","first-page":"11357","article-title":"Aberrant splicing in B-cell acute lymphoblastic leukemia","volume":"46","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib38-20230924","first-page":"E11","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","year":"2016","journal-title":"Am J Hematol"},{"key":"bib39-20230924","first-page":"E352","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","year":"2018","journal-title":"Am J Hematol"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","year":"2019","journal-title":"Nature"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","year":"2003","journal-title":"Nat Immunol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23266","article-title":"Lineage switch in childhood acute leukemia: an unusual event with poor outcome","volume":"87","year":"2012","journal-title":"Am J Hematol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy","volume":"63","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood-2002-06-1797","article-title":"Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing\/reactivation of the EBF\/Pax5 pathway","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0952-7915(99)00065-5","article-title":"Lineage commitment in lymphopoiesis","volume":"12","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib49-20230924","first-page":"4614","article-title":"Targeting primary pre-B cell acute lymphoblastic leukemia and CD19-negative relapses using trivalent CAR T cells","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","article-title":"T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","year":"2017","journal-title":"Cancer Cell"},{"key":"bib54-20230924","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","year":"2017","journal-title":"Sci Transl Med"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMcibr1814237","article-title":"Alternative splicing in tumors\u2014a path to immunogenicity?","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","year":"2018","journal-title":"Cancer Cell"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201905000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:16:27Z","timestamp":1695532587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201905000-00007"}},"subtitle":["Leukemia Immunoediting in the Age of Chimeric Antigen Receptors"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000381","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}